Laboratorios Farmaceuticos Rovi Statistics

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of GBP 2.80 billion. The enterprise value is 2.90 billion.

Market Cap	2.80B
Enterprise Value	2.90B

Important Dates

The next estimated earnings date is Tuesday, February 25, 2025.

Earnings Date	Feb 25, 2025
Ex-Dividend Date	Jul 8, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	18.61M

Valuation Ratios

The trailing PE ratio is 20.42.

PE Ratio	20.42
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	6.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.55, with an EV/FCF ratio of 52.99.

EV / Earnings	21.15
EV / Sales	4.35
EV / EBITDA	14.55
EV / EBIT	16.35
EV / FCF	52.99

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.23.

Current Ratio	2.50
Quick Ratio	0.92
Debt / Equity	0.23
Debt / EBITDA	0.54
Debt / FCF	1.95
Interest Coverage	69.72

Financial Efficiency

Return on equity (ROE) is 29.65% and return on invested capital (ROIC) is 20.37%.

Return on Equity (ROE)	29.65%
Return on Assets (ROA)	15.55%
Return on Invested Capital (ROIC)	20.37%
Return on Capital Employed (ROCE)	32.39%
Revenue Per Employee	315,059
Profits Per Employee	65,042
Employee Count	2,111
Asset Turnover	0.94
Inventory Turnover	0.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.73% in the last 52 weeks. The beta is 0.44, so Laboratorios Farmaceuticos Rovi's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	+3.73%
50-Day Moving Average	62.61
200-Day Moving Average	75.68
Relative Strength Index (RSI)	63.83
Average Volume (20 Days)	1,422

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of GBP 665.09 million and earned 137.30 million in profits. Earnings per share was 2.57.

Revenue	665.09M
Gross Profit	406.85M
Operating Income	176.89M
Pretax Income	176.19M
Net Income	137.30M
EBITDA	194.63M
EBIT	176.89M
Earnings Per Share (EPS)	2.57

Full Income Statement

Balance Sheet

The company has 14.61 million in cash and 106.74 million in debt, giving a net cash position of -92.14 million.

Cash & Cash Equivalents	14.61M
Total Debt	106.74M
Net Cash	-92.14M
Net Cash Per Share	n/a
Equity (Book Value)	464.49M
Book Value Per Share	8.55
Working Capital	276.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 105.00 million and capital expenditures -50.20 million, giving a free cash flow of 54.80 million.

Operating Cash Flow	105.00M
Capital Expenditures	-50.20M
Free Cash Flow	54.80M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 61.17%, with operating and profit margins of 26.60% and 20.64%.

Gross Margin	61.17%
Operating Margin	26.60%
Pretax Margin	26.49%
Profit Margin	20.64%
EBITDA Margin	29.26%
EBIT Margin	26.60%
FCF Margin	8.24%

Dividends & Yields

Laboratorios Farmaceuticos Rovi does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-16.25%
Years of Dividend Growth	n/a
Payout Ratio	34.21%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	4.90%
FCF Yield	1.95%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Laboratorios Farmaceuticos Rovi has an Altman Z-Score of 9.95.

Altman Z-Score	9.95
Piotroski F-Score	n/a